Charles Schwab Investment Management Inc. Sells 714,949 Shares of OPKO Health, Inc. (NASDAQ:OPK)

Charles Schwab Investment Management Inc. cut its stake in shares of OPKO Health, Inc. (NASDAQ:OPK - Free Report) by 17.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,497,406 shares of the biotechnology company's stock after selling 714,949 shares during the period. Charles Schwab Investment Management Inc. owned 0.51% of OPKO Health worth $5,141,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Intech Investment Management LLC purchased a new stake in shares of OPKO Health in the third quarter worth $190,000. FMR LLC raised its holdings in shares of OPKO Health by 103.6% in the 3rd quarter. FMR LLC now owns 21,795 shares of the biotechnology company's stock valued at $32,000 after acquiring an additional 11,089 shares in the last quarter. BNP Paribas Financial Markets boosted its position in shares of OPKO Health by 736.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 246,967 shares of the biotechnology company's stock valued at $368,000 after acquiring an additional 217,450 shares during the last quarter. Rubric Capital Management LP grew its holdings in shares of OPKO Health by 9.6% during the third quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company's stock worth $72,573,000 after purchasing an additional 4,284,336 shares in the last quarter. Finally, Verition Fund Management LLC purchased a new position in shares of OPKO Health during the third quarter worth about $201,000. 64.63% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, CEO Phillip Md Et Al Frost acquired 150,000 shares of the company's stock in a transaction dated Friday, January 17th. The stock was purchased at an average price of $1.47 per share, with a total value of $220,500.00. Following the completion of the purchase, the chief executive officer now owns 213,186,477 shares in the company, valued at $313,384,121.19. This trade represents a 0.07 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last three months, insiders have purchased 1,114,971 shares of company stock valued at $1,748,692. 49.69% of the stock is currently owned by insiders.

OPKO Health Price Performance

OPK traded down $0.04 during midday trading on Friday, hitting $1.70. The stock had a trading volume of 2,946,540 shares, compared to its average volume of 4,121,305. OPKO Health, Inc. has a 1 year low of $1.15 and a 1 year high of $2.04. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. The business has a fifty day moving average of $1.68 and a 200 day moving average of $1.58. The company has a market cap of $1.14 billion, a P/E ratio of -8.95 and a beta of 1.70.

OPKO Health (NASDAQ:OPK - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.08) by $0.09. The company had revenue of $183.60 million during the quarter, compared to analysts' expectations of $155.42 million. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. As a group, equities analysts forecast that OPKO Health, Inc. will post -0.25 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

OPK has been the subject of several research analyst reports. HC Wainwright reiterated a "buy" rating and set a $3.00 target price on shares of OPKO Health in a research report on Wednesday, March 19th. StockNews.com raised shares of OPKO Health from a "sell" rating to a "hold" rating in a report on Monday, March 3rd. Finally, Barrington Research reiterated an "outperform" rating and issued a $2.25 target price on shares of OPKO Health in a research report on Wednesday, March 12th.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.